Instantaneous Wave-Free Ratio-Guided vs Angiography-Guided Coronary Artery Bypass Grafting: 36-Months Graft Patency and Clinical Outcomes of a Randomized Trial

In a randomized trial, instantaneous wave-free ratio (iFR)-guided coronary artery bypass grafting significantly improved 36-month graft patency for both left internal mammary artery and saphenous vein grafts compared to conventional angiography-guided CABG by optimizing target selection and reducing competitive flow, although major adverse cardiac and cerebrovascular events remained similar between the two groups.

The Gist

The Big Picture: Fixing a Clogged Highway

Imagine your heart is a bustling city, and your coronary arteries are the main highways delivering fuel (blood) to the city center. Sometimes, these highways get clogged with traffic jams (plaque/stenosis). When the traffic gets bad enough, the city needs a detour, or a bypass, to keep the fuel flowing. This surgery is called CABG (Coronary Artery Bypass Grafting).

In this surgery, doctors take a healthy vein or artery from another part of your body (like a spare pipe) and sew it onto the heart to go around the clog.

The Problem: The "False Alarm" Detour

For years, doctors decided where to put these detours by looking at an X-ray of the arteries (angiography). It's like looking at a map and seeing a road that looks narrow. So, they build a detour.

But here's the catch: Just because a road looks narrow on a map doesn't mean traffic is actually stuck. Sometimes, the cars are moving just fine despite the narrowness.

• If a doctor builds a detour for a road that isn't actually clogged, the native blood flow (the original road) and the new detour fight each other.
• This is called competitive flow. It's like opening a second lane on a highway that was already moving fast; the cars get confused, the new lane gets empty, and eventually, the new lane closes down (the graft fails).

The New Idea: The "Traffic Sensor" (iFR)

This study tested a new way to decide where to build the detours. Instead of just looking at the map (angiography), the doctors used a high-tech traffic sensor called iFR (Instantaneous Wave-Free Ratio).

• The Analogy: Think of the angiography as a satellite photo of a road. It shows the road is narrow.
• The iFR is like a live traffic camera that tells you, "Hey, even though the road is narrow, cars are still moving at 60 mph. No need for a detour!" or "The road is narrow, and cars are stopped at 5 mph. Build the detour!"

The Experiment: Map vs. Sensor

The researchers took 100 patients who needed heart bypass surgery and split them into two teams:

1. Team A (The Old Way): Surgeons built detours based only on the "satellite photo" (angiography).
2. Team B (The New Way): Surgeons used the "traffic sensor" (iFR) first. If the sensor said the road was fine, they didn't build a detour there. They only built detours where the sensor confirmed a real blockage.

The Results: 3 Years Later

The researchers checked on the patients 3 years later to see how the "pipes" (grafts) were holding up.

• The Winner: Team B (The Sensor Team) had much better results.
  • Their detours stayed open and working much more often.
  • Specifically, the main artery grafts (LIMA) stayed open 80.5% of the time, compared to only 56.8% for Team A.
  • The vein grafts also did much better (90% vs 70%).
• Why? Team B avoided building detours on roads that didn't need them. By not fighting the natural traffic flow, their new pipes stayed healthy.
• The "Grey Zone": The study found a specific "tipping point." If the sensor reading was above a certain number (0.875), the new pipe was almost guaranteed to fail because the native blood flow was too strong.

Did Patients Feel Better?

Interestingly, while the pipes worked better in Team B, the patients in both groups reported feeling roughly the same regarding chest pain and survival rates after 3 years.

• The Takeaway: This might be because 3 years isn't long enough to see the full benefit. However, having better pipes means fewer future heart attacks and fewer repeat surgeries down the road. It's like having a better foundation for a house; the house looks the same today, but it will last much longer tomorrow.

The Bottom Line

This study suggests that before performing heart bypass surgery, doctors should use a "traffic sensor" (iFR) to double-check if a blockage is actually causing a traffic jam.

The Lesson: Don't just fix what looks broken; fix what is actually broken. This simple check prevents unnecessary surgery, saves resources, and ensures that the life-saving detours doctors build actually stay open for the long haul.

Technical Summary

1. Problem Statement

Coronary Artery Bypass Grafting (CABG) is the gold standard for complex multivessel coronary artery disease (CAD). However, a significant limitation is graft failure, which occurs in up to 50% of cases over 10 years. A primary mechanism for this failure is competitive flow: when a graft is placed on a coronary stenosis that is angiographically visible (50–75% narrowing) but physiologically non-significant (does not restrict blood flow), the native vessel continues to supply adequate blood. This competition causes the graft to atrophy, leading to occlusion or hypoperfusion.

Current surgical planning often relies solely on angiography, which can overestimate lesion severity. While physiological assessment tools like Fractional Flow Reserve (FFR) and Instantaneous Wave-Free Ratio (iFR) are standard in Percutaneous Coronary Intervention (PCI), their utility in guiding surgical target selection for CABG remains debated, with some trials (e.g., GRAFFITI) showing no benefit. There is a lack of prospective randomized evidence regarding whether iFR-guided CABG improves mid-term graft patency compared to standard angiography-guided CABG.

2. Methodology

• Study Design: A prospective, randomized, single-blind, single-center controlled trial conducted at the Lithuanian University of Health Sciences (2018–2021).
• Population: 110 patients with stable angina and multivessel CAD, specifically those with at least one intermediate stenosis (50%–75%) identified via angiography.
• Randomization: Patients were randomized 1:1 into two groups:
  1. Angiography-Guided Group: Grafting decisions based solely on visual/quantitative angiographic assessment.
  2. iFR-Guided Group: Grafting decisions based on angiography plus iFR assessment.
     • Protocol: Lesions with iFR ≤ 0.89 were deemed significant and grafted. Lesions with iFR ≥ 0.90 were deferred (not grafted).
     • Exception: The Left Internal Mammary Artery (LIMA) to Left Anterior Descending (LAD) graft was performed in all patients regardless of iFR values due to established survival benefits.
• Intervention: All patients underwent standard CABG using arterial and venous conduits. iFR measurements were blinded to the surgical team until after the decision to proceed with surgery was made (though in the iFR arm, unblinding occurred pre-surgery to determine graft targets).
• Follow-up & Endpoints:
  • Primary Endpoint: Graft patency (defined as occlusion or hypoperfusion) evaluated via Coronary Computed Tomography Angiography (CCTA) at 2, 12, and 36 months.
  • Secondary Endpoints: Major Adverse Cardiac and Cerebrovascular Events (MACCE), including cardiovascular death, non-fatal MI, stroke, and target vessel revascularization (TVR).
• Statistical Analysis: Used Chi-square/Fisher's exact tests for categorical data, Mann-Whitney U for non-parametric continuous data, and logistic regression to identify predictors of graft failure.

3. Key Contributions

• First Prospective Randomized Trial: This study provides the first prospective randomized evidence specifically comparing iFR-guided versus angiography-guided CABG strategies.
• Identification of a Critical Threshold: The study identified a pre-operative iFR threshold of >0.875 as a potent predictor of subsequent graft occlusion or hypoperfusion at 36 months.
• Physiological Optimization: It demonstrates that physiological assessment allows surgeons to avoid grafting "grey zone" or non-flow-limiting lesions, thereby reducing competitive flow.
• Differentiation of Conduit Types: The study provides specific data on how physiological guidance impacts both arterial (LIMA) and venous (Saphenous Vein) grafts separately.

4. Key Results

• Graft Patency (Primary Outcome):
  • Overall: At 36 months, the rate of graft occlusion/hypoperfusion was significantly lower in the iFR-guided group (15.15%) compared to the angiography-guided group (32.82%; P = 0.007).
  • LIMA-to-LAD Grafts: Patency was significantly higher in the iFR group (80.5%) vs. the angiography group (56.8%; P = 0.03).
    • Subgroup analysis showed that if pre-CABG iFR was <0.85**, patency was **90.0%**. If iFR was **>0.90, patency dropped to 29.4%.
    • An iFR >0.875 was associated with a 12-fold higher odds of graft failure at 36 months.
  • Saphenous Vein Grafts (SVG): Patency was significantly higher in the iFR group (90.2%) vs. the angiography group (70.3%; P = 0.046).
• Procedural Metrics:
  • The iFR-guided group received a significantly lower number of grafts (median 3) compared to the angiography group (median 3.5; P = 0.001), indicating that physiological assessment successfully identified lesions that did not require revascularization.
  • Surgery duration and hospital stay were comparable between groups.
• Clinical Outcomes (MACCE):
  • There was no statistically significant difference in MACCE rates at 36 months (28% in iFR group vs. 20% in angiography group; P = 0.48).
  • No myocardial infarctions were reported in either group.
• Follow-up: 78% of patients completed the 36-month follow-up.

5. Significance and Clinical Implications

• Paradigm Shift in Surgical Planning: The study suggests that routine preoperative physiological assessment (iFR) should be integrated into surgical planning for multivessel CAD. This moves the field from purely anatomical decision-making to physiology-driven decision-making.
• Reducing Unnecessary Surgery: By identifying non-significant stenoses, surgeons can avoid placing unnecessary grafts, which reduces the risk of competitive flow-induced graft failure.
• Improved Conduit Durability: The data strongly supports that grafting only hemodynamically significant lesions significantly improves the mid-term durability of both arterial and venous conduits.
• Future Outlook: While MACCE rates were similar at 36 months (likely due to sample size and follow-up duration), the superior graft patency suggests that iFR-guided CABG may lead to better long-term clinical outcomes and reduced need for repeat revascularization over a longer horizon.
• Limitations: The study was single-center with a moderate sample size, and the 36-month follow-up may be insufficient to capture late-term clinical divergence. However, the robustness of the patency data provides a strong basis for changing surgical protocols.

Conclusion: iFR-guided CABG significantly improves mid-term graft patency by optimizing target selection and minimizing competitive flow, representing a significant advancement in the optimization of coronary artery bypass surgery outcomes.